9.88
-0.46 (-4.45%)
| Previous Close | 10.34 |
| Open | 10.40 |
| Volume | 540,506 |
| Avg. Volume (3M) | 1,320,821 |
| Market Cap | 537,669,440 |
| Price / Sales | 195.11 |
| Price / Book | 1.66 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Operating Margin (TTM) | -5,656.01% |
| Diluted EPS (TTM) | -1.67 |
| Quarterly Revenue Growth (YOY) | -11.60% |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 47.43 |
| Operating Cash Flow (TTM) | -82.78 M |
| Levered Free Cash Flow (TTM) | -70.18 M |
| Return on Assets (TTM) | -16.91% |
| Return on Equity (TTM) | -28.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Upstream Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.84% |
| % Held by Institutions | 89.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 3,143,078 |
| Altshuler Shaham Ltd | 31 Dec 2025 | 1,341,540 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2025 | 1,329,544 |
| Omega Fund Management, Llc | 31 Dec 2025 | 1,326,293 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |